Frailty Score and Postoperative Morbidity in Colorectal Cancer Surgery
Launched by DR ABDURRAHMAN YURTASLAN ANKARA ONCOLOGY TRAINING AND RESEARCH HOSPITAL · Mar 5, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how frailty affects recovery after surgery for colorectal cancer in older patients. Frailty refers to a person's overall health and strength, and it can make recovery from surgery more challenging. The researchers are particularly interested in using a tool called the Edmonton Frailty Index to assess frailty in patients aged 65 and older who are scheduled for elective (non-emergency) colorectal cancer surgery. They will track various outcomes after surgery, such as complications, how long patients spend in the hospital or intensive care, and any serious problems that might occur within 30 days of the operation.
To be eligible for this trial, patients must be at least 65 years old, scheduled for elective surgery for colorectal cancer, and able to undergo a frailty assessment. Those with severe health issues or who cannot give informed consent will not be included. Participants can expect to have their frailty assessed before surgery and will be monitored closely afterward to gather important information about recovery. This study aims to improve how doctors assess risks and manage care for older patients undergoing colorectal cancer surgery, ultimately helping to enhance their recovery and outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 65 years and older
- • Patients undergoing surgery for colorectal cancer
- • Patients scheduled for elective (non-emergency) surgery
- • Individuals eligible for preoperative frailty assessment using the Edmonton Frailty Scale (EFS)
- • Patients who can be followed for at least 30 days postoperatively
- • Patients able to provide informed consent
- Exclusion Criteria:
- • Patients requiring emergency surgery
- • Neurological or psychiatric disorders that prevent the assessment of consciousness level
- • Severe comorbidities (Patients with extremely high surgical risk due to severe cardiovascular, respiratory, or other systemic diseases)
- • Patients who do not or cannot provide informed consent
About Dr Abdurrahman Yurtaslan Ankara Oncology Training And Research Hospital
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital is a leading institution dedicated to advancing cancer care and research in Turkey. With a strong focus on innovative oncology treatments and comprehensive training programs, the hospital serves as a pivotal center for clinical trials aimed at improving patient outcomes. Its multidisciplinary team of specialists collaborates to explore cutting-edge therapeutic approaches, ensuring adherence to the highest standards of clinical research and patient safety. The hospital's commitment to excellence positions it as a key player in the global oncology research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Yenimahalle, Turkey
Patients applied
Trial Officials
Mustafa Kemal SAHIN
Principal Investigator
Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported